Cellevate announces the appointment of renowned industrial biotechnology and bioprocessing expert Dr. Uwe Gottschalk as new Chairman of the Board of Directors
LUND, Sweden, March 14, 2024 – Cellevate AB, an innovative biotech company developing the next generation of cell culture systems designed to revolutionize biomanufacturing, announces that Dr. Uwe Gottschalk has been elected as Chairman to its Board of Directors. The appointment follows the resignation of Mats Leifland, who served as Chairman of the Board until March 12, 2024.
Dr. Gottschalk brings a wealth of experience within the field of biotechnology, boasting a distinguished career highlighted by significant achievements. He currently serves as an Operating Partner at Keensight Capital. Dr. Gottschalk holds a Ph.D. in Chemistry for early work on antibody drug conjugates back in 1987 and was awarded the Bioprocessing Lifetime Achievement Award (2021) after some 30 years in the biotech industry. Previously, Dr. Gottschalk served as Group Vice President at Sartorius Stedim Biotech (2004-2014), with a global responsibility for all bioseparation-related process technology. Before joining Keensight Capital in 2022 he was Chief Technology Officer (2014-2017) and Chief Scientific Officer (2017-2021) at Lonza where he established and led the global Research and Technology organisation.
“Dr. Uwe Gottschalk's appointment as new Chairman marks a major milestone for Cellevate. With his extensive industry knowledge, decades of experience, and invaluable network connections, Dr. Uwe Gottschalk is well-suited to lead Cellevate into its next phase of growth and commercialization. I am confident that under Dr. Gottschalk's guidance, Cellevate will continue to thrive and achieve new heights of success,” says Mats Leifland, the departing Chairman of Cellevate's Board.
“I am thrilled to be Joining Cellevate as the new Chairman and to become part of such a dynamic and innovative company. I am looking forward to working with the Board of Directors and the Cellevate team to contribute to successful launch and commercialization of our unique nanotechnology in the field of bioprocessing” says Dr. Gottschalk.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a spin out from NanoLund - a world leading nanomaterial academic center, at Lund University in Sweden. The company develops and markets products based on a proprietary nanofiber-based platform - the Cellevat3d™ - a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of nanofiber materials – “microcarriers” - with unparalleled surface area for cell growth, reproducibility and customization, which ultimately lead to an improved biomanufacturing productivity and process economy. Cellevat3d™ microcarriers products are designed as an integrated part of upstream bioprocess solutions, starting with laboratory testing of cell lines followed by pilot and large-scale batch production of gene therapies. Cellevat3d™ microcarriers launch is planned for 2024.
For more information, please visit www.cellevate.com.
